A continuing black hole? the FDA boxed warning: An appeal to improve its clinical utility

Clinical Toxicology

Volumn 49, Issue 6, 2011, Pages 443-447

  Matlock, Aaron ^a   Allan, Nicholas ^a   Wills, Brandon ^b   Kang, Christopher ^a   Leikin, Jerrold B ^c  

^a MADIGAN ARMY MEDICAL CENTER   (United States)

^b VCU Medical Center   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Adverse drug reaction; FDA; Recall

Indexed keywords

AMFEBUTAMONE; BROMFENAC; CISAPRIDE; DROPERIDOL; FELBAMATE; FENTANYL; METHADONE; METOCLOPRAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; WARFARIN; ZOMEPIRAC;

ADVERSE OUTCOME; BLEEDING; BOXED WARNING; CARDIOTOXICITY; DATA BASE; DRUG INFORMATION; DRUG LABELING; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE UTILIZATION; HEART ARRHYTHMIA; HUMAN; INCIDENCE; POISON CENTER; POSTOPERATIVE NAUSEA AND VOMITING; PRESCRIPTION; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; TARDIVE DYSKINESIA; TENDON RUPTURE; TORSADE DES POINTES;

ANTIPSYCHOTIC AGENTS; DROPERIDOL; DRUG LABELING; HISTORY, 20TH CENTURY; HUMANS; METHADONE; NARCOTICS; PHARMACEUTICAL PREPARATIONS; PRESCRIPTION DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80051779618     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2011.564585     Document Type: Review

References (41)

1. Associated Press 2009. FDA ' s drug approvals flat in 2009, safety up, http://www.msnbc.msn.com/id/34708085/ns/health-more-health-news/. Accessed 23 February 2011.
2. Food and Drug Administration (FDA) 1979. 21 Code of Federal Regulations xx201.56, 201.57.
3. Food and Drug Administration (FDA) 1979. 21 Code of Federal Regulations x201.57(e).
4. Guidance for Industry Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products-Content and Format DRAFT GUIDANCE, January 2006. http://www.fda.gov/ downloads/ Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ ucm075096. pdf. Accessed 23 February 2011.
5. Liang BA. FDA use of the black box warning: Time for reevaluation as a safety tool. J Clin Anesth 2002; 14:561-563. (Pubitemid 36143655)
6. Wood AJ. Thrombotic thrombocytopenic purpura and clopidogrel-a need for new approaches to drug safety. N Engl J Med 2000; 342: 1824-1826. (Pubitemid 30390244)
7. Food and Drug Administration (FDA) 2009. Dr. Curtis Rosebraugh (Director of Drug Evaluation II in the Center for Drug Evaluation and Research at FDA) from the Transcript for FDA ' s Media Briefi ng on the Serious Mental Health Risks Associated with the Drugs Chantix and Zyban, 1 July 2009. www.fda.gov/downloads/News Events/Newsroom/Media/transcripts. Accessed 23 February 2011.
8. Cook DM, Gurugubelli RK, Bero LA. Risk management policy and black-box warnings: A qualitative analysis of US FDA proceedings. Drug Saf 2009; 32:1057-1066.
9. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287:2215-2220. (Pubitemid 34441937)
10. Lurie P, Sasich LD. Safety of FDA-approved drugs. JAMA 1999; 282:2297-2298.
11. -2006 Safety Alerts for Human Medical Products, FDA, U.S. Department of Health and Human Services. www.fda.gov/safety/ Med-Watch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/. Accessed 23 February 2011.
12. Droperidol [package insert]. Taylor Pharmaceuticals. Decatur, IL. 2006.
13. Gan TJ. " Black box' warning on droperidol: Report of the FDA convened expert panel. Anesth Analg 2004; 98:1809. (Pubitemid 38668940)
14. Fortney JT, Gan TJ, Graczyk S, Wetchler B, Melson T, Khalil S, et al. A comparison of the effi cacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. Anesth Analg 1998; 86:731-738. (Pubitemid 28177723)
15. Henzi I, Sonderegger J, Tramer MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth 2000; 47:537-551.
16. Bailey P, Norton R, Karan S. The FDA droperidol warning: Is it justified? Anesthesiology 2002; 97:288-289.
17. Gan TJ, White PF, Scuderi PE, Watcha MF, Kovac A. FDA " black box " warning regarding use of droperidol for postoperative nausea and vomiting: Is it justified? Anesthesiology 2002; 97:287. (Pubitemid 34733963)
18. Habib AS, Gan TJ. Food and drug administration black box warning on the perioperative use of droperidol: A review of the cases. Anesth Analg 2003; 96:1377-1379. (Pubitemid 36512879)
19. Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health Syst Pharm 2007; 64:1174-1186. (Pubitemid 46849308)
20. Kao LW, Kirk MA, Evers SJ, Rosenfeld SH. Droperidol, QT prolongation, and sudden death: What is the evidence? Ann Emerg Med 2003; 41:546-558.
21. Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994; 79:983-986. (Pubitemid 24324682)
22. Smith SW, Martel M, Biros M. QT lengthening after parenteral droperidol administration. Acad Emerg Med 2002; 9:374-375.
23. Mieckowski A, Burns M. Droperidol and the Blackbox. Clin Toxicol (Phila) 2005; 40:669-670 (abstract).
24. Habib AS, Gan TJ. The use of droperidol before and after the Food and Drug Administration black box warning: A survey of the members of the Society of Ambulatory Anesthesia. J Clin Anesth 2008; 20:35-39. (Pubitemid 351381411)
25. Nuttall GA, Eckerman KM, Jacob KA, Pawlaski EM, Wigersma SK, Marienau ME, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology 2007; 107:531-536. (Pubitemid 47480557)
26. Methadone-associated Deaths and Efforts to Prevent Them. Government Accountability Office Report to Congressional Requesters: GAO-09-341; March, 2009.
27. Paulozzi LJ, Logan JE, Hall AJ, McKinstry E, Kaplan JA, Crosby AE. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction 2009; 104: 1541-1548.
28. Sims SA, Snow LA, Porucznik CA. Surveillance of methadonerelated adverse drug events using multiple public health data sources. J Biomed Inform 2007; 40:382-389. (Pubitemid 47187788)
29. Wysowski DK. Surveillance of prescription drug-related mortality using death certificate data. Drug Saf 2007; 30:533-540. (Pubitemid 46873078)
30. Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 2008; 52:879-889. (Pubitemid 351951756)
31. Li Y, Kantelip JP, Gerritsen-van SP, Davani S. Interindividual variability of methadone response: Impact of genetic polymorphism. Mol Diagn Ther 2008; 12:109-124. (Pubitemid 351570866)
32. Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med 2008; 9: 315-344. (Pubitemid 351467888)
33. Andrews CM, Krantz MJ, Wedam EF, Marcuson MJ, Capacchione JF, Haigney MC. Methadone-induced mortality in the treatment of chronic pain: Role of QT prolongation. Cardiol J 2009; 16:210-217.
34. Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: Improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf 2007; 6:289-303. (Pubitemid 46767636)
35. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2005; 11:44-49. (Pubitemid 40082210)
36. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: Reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005; 14:747-753. (Pubitemid 41684467)
37. Methadone [package insert]. Roxane Laboratories, Inc. Columbus, OH.
38. Bronstein AC, Spyker DA, Cantilena LR Jr., Green JL, Rumack BH, Giffin SL. 2008. Annual Report of the American Association of Poison Control Centers ' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911-1084.
39. Litovitz TL, Klein-Schwartz W, White S, Cobaugh DJ, Youniss J, Omslaer JC, et al. 2000. Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2001; 19:337-395.
40. Krantz MJ, Rowan SB, Schmittner J, Bucher BB. Physician awareness of the cardiac effects of methadone: Results of a national survey. J Addict Dis 2007; 26:79-85.
41. Dershwitz, M. There should be a threshold dose for FDA black-box warning on droperidol. Anesth Analg. 2003; 97:1542-1543; author reply 1543. (Pubitemid 37310168)